Chester Donald Smith Iii, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1212 Garfield Ave, Suite 300, Parkersburg, WV 26101 Phone: 304-865-3600 Fax: 304-865-3600 |
William E Cartwright, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1907 Ann St, Parkersburg, WV 26101 Phone: 304-424-4205 Fax: 304-424-4283 |
Richard W Watson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2610 Camden Ave, Parkersburg, WV 26101 Phone: 304-917-3733 Fax: 304-917-3750 |
Robert B Dushkoff, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 517 36th St, Parkersburg, WV 26101 Phone: 304-865-5544 |
Dr. Douglas Paul Brooks, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1512 36th St, Parkersburg, WV 26104 Phone: 304-893-9251 Fax: 304-893-9152 |
Christopher James Edmands, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 418 Grand Park Dr, Suite 312, Parkersburg, WV 26105 Phone: 304-422-3435 Fax: 304-422-3430 |
News Archive
A Portsmouth academic's research project has been shortlisted for an award by the Royal Institute of British Architects (RIBA).
Sonar and ultrasound, which use sound as a navigational device and to paint accurate pictures of an environment, are the basis of countless technologies, including medical ultrasound machines and submarine navigation systems. But when it comes to more accurate sonar and ultrasound, animals' "biosonar" capabilities still have the human race beat.
A research team led by the National Neuroscience Institute has uncovered a novel function of the Amyloid Precursor Protein (APP), one of the main pathogenic culprits of Alzheimer's disease. This discovery may help researchers understand how the protein goes awry in the brains of Alzheimer's disease patients, and potentially paves the way for the development of innovative therapeutics to improve the brain function of dementia patients.
Catalyst Pharmaceutical Partners, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.
› Verified 4 days ago